Source: http://belmorelaw.com/our-cases/?Person=Peter%20Wilcox
Timestamp: 2019-04-24 14:39:36+00:00

Document:
May 31, 2016 2016 FCA 161 Pfizer Canada Inc. v. Teva Canada Limited We overturned a section 8 damages award in excess of $100 million against our client, Pfizer, in respect of generic venlafaxine.
May 27, 2016 2016 FC 581 Bayer Inc. et al. v Fresenius Kabi Canada Ltd. et al. We obtained an order preventing Fresenius from obtaining approval to market a generic version of Bayer’s AVELOX IV product until expiry of Bayer’s patent.
Sep 16, 2015 2015 FCA 192 Actavis Pharma Company v. Alcon Canada Inc. We successfully resisted Actavis’ appeal of the trial judge’s finding that the basic compound patent protecting VIGAMOX was valid.
May 7, 2014 2014 FC 436 Bayer Inc. and Bayer Pharma Aktiengesellschaft v. Apotex Inc. and the Minister of Health The validity of Bayer’s key patent covering the oral contraceptives YASMIN® and YAZ® was upheld by the Federal Court.
Apr 3, 2014 2014 FC 248 Teva Canada Limited v. Pfizer Canada Inc. We represented Pfizer in defending a damages case pursuant to section 8 of the Patented Medicines (Notice of Compliance) Regulations.
Apr 14, 2010 2010 FC 409 Pfizer Canada Inc. v. Novopharm Limited Peter Wilcox acted for Pfizer in various proceedings relating to pregabalin (LYRICA®).
Jun 26, 2009 2009 FC 671 Pfizer Canada Inc. v. Apotex Inc. Peter Wilcox acted for Pfizer in a proceeding related to amlodipine (NORVASC®), including successfully resisting a motion to dismiss.
Oct 24, 2008 2008 FC 1195 Lotech Medical Systems Limited v. Kinetic Concepts Inc. Peter Wilcox acted Kinetic Concepts in the Federal Court in a patent infringement and validity action related to therapeutic mattresses.
Dec 7, 2006 2006 FC 1471 Pfizer Canada Inc. v. Canada (Minister of Health) - 2006 FC 1471 Pfizer in the Federal Court and Federal Court of Appeal in proceedings related to atorvastatin (LIPITOR®) against various generic drug companies.

References: v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v. 
 v.